This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kearon, C. Search for Related Content PubMed PubMed Citation Articles by Kearon, C. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Pulmonary Embolism

(Circulation. 2004;110:I-10 – I-18.)
© 2004 American Heart Association, Inc.

Treatment of Venous Thromboembolism

Long-Term Management of Patients After Venous Thromboembolism

Clive Kearon, MB, MRCPI, FRCPC, PhD

From the Department of Medicine, McMaster University, McMaster Clinic, Henderson General Hospital, Hamilton, Ontario, Canada.

Correspondence to Dr Clive Kearon, McMaster University, McMaster Clinic, Henderson General Hospital, Hamilton Health Sciences, 711 Concession St, Hamilton, Ontario, Canada L8V 1C3. E-mail kearonc{at}mcmaster.ca

Long-term treatment of venous thromboembolism (VTE) focuses mainly on the duration of anticoagulant therapy, usually with vitamin K (VK) antagonists. The duration of therapy should be individualized based on the risk of recurrent VTE if treatment were stopped and the risk of bleeding if treatment were continued. The risk of recurrence is low if thrombosis was provoked by a major reversible risk factor such as surgery; 3 months of treatment is usually adequate for such patients. The risk of recurrence is high if thrombosis was unprovoked ("idiopathic") or associated with an irreversible risk factor such as cancer; anticoagulant treatment for at least 6 months, and often indefinitely, is indicated for such patients. Risk of recurrence is intermediate if thrombosis was associated with a minor transient risk factor; such patients can be treated for 3 to 6 months. Within each of these categories, presentation as pulmonary embolism, >1 previous VTE, an underlying malignancy, an antiphospholipid antibody, or selected hereditary thrombophilic states favor more prolonged therapy, whereas isolated distal deep vein thrombosis, high risk of bleeding, and patient preference favor shorter treatment. The optimal intensity of anticoagulant therapy with VK antagonists corresponds to a target international normalized ratio of 2.5 (range, 2.0 to 3.0). Long-term treatment with low-molecular-weight heparin is an alternative to VK-antagonist therapy and is usually preferable in patients with active cancer. Oral direct thrombin inhibitors also appear suitable for long-term prevention of recurrent VTE but await regulatory approval and comparison with VK antagonists.

Key Words: deep vein thrombosis • pulmonary embolism • anticoagulant therapy • warfarin

This article has been cited by other articles:

				W. K. Ho, G. J. Hankey, D. J. Quinlan, and J. W. Eikelboom Risk of recurrent venous thromboembolism in patients with common thrombophilia: a systematic review. Arch Intern Med, April 10, 2006; 166(7): 729 - 736. [Abstract] [Full Text] [PDF]